hVIVO PLC
LSE:HVO
Intrinsic Value
hVIVO PLC provides pharmaceutical development services. [ Read More ]
The intrinsic value of one HVO stock under the Base Case scenario is 24.29 GBX. Compared to the current market price of 28.25 GBX, hVIVO PLC is Overvalued by 14%.
Valuation Backtest
hVIVO PLC
Run backtest to discover the historical profit from buying and selling HVO stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
hVIVO PLC
Current Assets | 52m |
Cash & Short-Term Investments | 37m |
Receivables | 14.6m |
Other Current Assets | 426k |
Non-Current Assets | 31.2m |
PP&E | 20m |
Intangibles | 5.7m |
Other Non-Current Assets | 5.5m |
Current Liabilities | 35.2m |
Accounts Payable | 34.2m |
Other Current Liabilities | 952k |
Non-Current Liabilities | 13.7m |
Long-Term Debt | 12.2m |
Other Non-Current Liabilities | 1.6m |
Earnings Waterfall
hVIVO PLC
Revenue
|
56m
GBP
|
Operating Expenses
|
-45.7m
GBP
|
Operating Income
|
10.3m
GBP
|
Other Expenses
|
5.8m
GBP
|
Net Income
|
16.1m
GBP
|
Free Cash Flow Analysis
hVIVO PLC
HVO Profitability Score
Profitability Due Diligence
hVIVO PLC's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
Score
hVIVO PLC's profitability score is 67/100. The higher the profitability score, the more profitable the company is.
HVO Solvency Score
Solvency Due Diligence
hVIVO PLC's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Score
hVIVO PLC's solvency score is 65/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
HVO Price Targets Summary
hVIVO PLC
According to Wall Street analysts, the average 1-year price target for HVO is 34.61 GBX with a low forecast of 29.29 GBX and a high forecast of 39.9 GBX.
Shareholder Return
HVO Price
hVIVO PLC
Average Annual Return | 116.84% |
Standard Deviation of Annual Returns | 225.43% |
Max Drawdown | -81% |
Market Capitalization | 192.2m GBX |
Shares Outstanding | 680 371 968 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.
Contact
IPO
Employees
Officers
The intrinsic value of one HVO stock under the Base Case scenario is 24.29 GBX.
Compared to the current market price of 28.25 GBX, hVIVO PLC is Overvalued by 14%.